HQY Quote, Financials, Valuation and Earnings

HealthStream, Inc. has a net margin of 16.05% compared to HealthEquity, Inc.'s net margin of 3.18%. HealthEquity, Inc.'s return on equity of 9.01% beat HealthStream, Inc.'s return on equity of 5.16%.

HealthEquity, Inc. has a consensus price target of $114.44, signalling upside risk potential of 49.61%. On the other hand HealthStream, Inc. has an analysts' consensus of $30.50 which suggests that it could grow by 43.67%. Given that HealthEquity, Inc. has higher upside potential than HealthStream, Inc., analysts believe HealthEquity, Inc. is more attractive than HealthStream, Inc..

HealthEquity, Inc. has a beta of 0.239, which suggesting that the stock is 76.091% less volatile than S&P 500. In comparison HealthStream, Inc. has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.064%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthStream, Inc. offers a yield of 0.58% to investors and pays a quarterly dividend of $0.03 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. HealthStream, Inc. pays out 20.38% of its earnings as a dividend. HealthStream, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity, Inc. quarterly revenues are $322.2M, which are larger than HealthStream, Inc. quarterly revenues of $79.7M. HealthEquity, Inc.'s net income of $51.7M is higher than HealthStream, Inc.'s net income of $2.5M. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 35.06x while HealthStream, Inc.'s PE ratio is 34.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 5.22x versus 2.10x for HealthStream, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scienture Holdings, Inc. has a net margin of 16.05% compared to HealthEquity, Inc.'s net margin of -611.42%. HealthEquity, Inc.'s return on equity of 9.01% beat Scienture Holdings, Inc.'s return on equity of -24.88%.

HealthEquity, Inc. has a consensus price target of $114.44, signalling upside risk potential of 49.61%. On the other hand Scienture Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 248.76%. Given that Scienture Holdings, Inc. has higher upside potential than HealthEquity, Inc., analysts believe Scienture Holdings, Inc. is more attractive than HealthEquity, Inc..

HealthEquity, Inc. has a beta of 0.239, which suggesting that the stock is 76.091% less volatile than S&P 500. In comparison Scienture Holdings, Inc. has a beta of 3.033, suggesting its more volatile than the S&P 500 by 203.315%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scienture Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.50 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Scienture Holdings, Inc. pays out 81.44% of its earnings as a dividend. Scienture Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity, Inc. quarterly revenues are $322.2M, which are larger than Scienture Holdings, Inc. quarterly revenues of $590K. HealthEquity, Inc.'s net income of $51.7M is higher than Scienture Holdings, Inc.'s net income of -$3.6M. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 35.06x while Scienture Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 5.22x versus 8.44x for Scienture Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Simulations Plus, Inc. has a net margin of 16.05% compared to HealthEquity, Inc.'s net margin of 3.67%. HealthEquity, Inc.'s return on equity of 9.01% beat Simulations Plus, Inc.'s return on equity of -42.84%.

HealthEquity, Inc. has a consensus price target of $114.44, signalling upside risk potential of 49.61%. On the other hand Simulations Plus, Inc. has an analysts' consensus of $24.67 which suggests that it could grow by 101.69%. Given that Simulations Plus, Inc. has higher upside potential than HealthEquity, Inc., analysts believe Simulations Plus, Inc. is more attractive than HealthEquity, Inc..

HealthEquity, Inc. has a beta of 0.239, which suggesting that the stock is 76.091% less volatile than S&P 500. In comparison Simulations Plus, Inc. has a beta of 1.120, suggesting its more volatile than the S&P 500 by 11.977%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.06 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Simulations Plus, Inc. pays out -48.18% of its earnings as a dividend.

HealthEquity, Inc. quarterly revenues are $322.2M, which are larger than Simulations Plus, Inc. quarterly revenues of $18.4M. HealthEquity, Inc.'s net income of $51.7M is higher than Simulations Plus, Inc.'s net income of $676K. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 35.06x while Simulations Plus, Inc.'s PE ratio is 49.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 5.22x versus 3.14x for Simulations Plus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nano Mobile Healthcare has a net margin of 16.05% compared to HealthEquity, Inc.'s net margin of --. HealthEquity, Inc.'s return on equity of 9.01% beat Nano Mobile Healthcare's return on equity of --.

HealthEquity, Inc. has a consensus price target of $114.44, signalling upside risk potential of 49.61%. On the other hand Nano Mobile Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that HealthEquity, Inc. has higher upside potential than Nano Mobile Healthcare, analysts believe HealthEquity, Inc. is more attractive than Nano Mobile Healthcare.

HealthEquity, Inc. has a beta of 0.239, which suggesting that the stock is 76.091% less volatile than S&P 500. In comparison Nano Mobile Healthcare has a beta of -1.161, suggesting its less volatile than the S&P 500 by 216.13%.

HealthEquity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nano Mobile Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity, Inc. pays -- of its earnings as a dividend. Nano Mobile Healthcare pays out -- of its earnings as a dividend.

HealthEquity, Inc. quarterly revenues are $322.2M, which are larger than Nano Mobile Healthcare quarterly revenues of --. HealthEquity, Inc.'s net income of $51.7M is higher than Nano Mobile Healthcare's net income of --. Notably, HealthEquity, Inc.'s price-to-earnings ratio is 35.06x while Nano Mobile Healthcare's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity, Inc. is 5.22x versus -- for Nano Mobile Healthcare. Usually stocks with elevated PS ratios are considered overvalued.